v3.26.3
Revenues
 9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenues REVENUES:
Revenues by Product Line. The following table represents total net revenues by product line:
HIV
Sample Management Solutions (1)
HCV
Other products and services revenues (2)
COVID-19 (3)
Risk Assessment Testing (4)
Net product and services revenues
Non-product and services revenues (5)
Net revenues
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2026202520262025
$12,116 $11,141 $39,305 $38,439 
12,498 10,306 31,431 29,271 
3,221 2,604 9,277 11,063 
2,235 1,196 6,138 2,963 
22 89 41 578 
— — — 1,866 
30,092 25,336 86,192 84,180 
815 1,749 3,279 4,078 
$30,907 $27,085 $89,471 $88,258 
(1) Includes Genomics, Microbiome and Colli-Pee® product revenues.
(2) Includes Syphilis, Ebola, and Sickle SCAN® product revenues and single order fulfillment.
(3) Includes COVID-19 Diagnostics and COVID-19 Sample Management Solutions revenues.
(4) Includes substance abuse testing product revenues.
(5) Includes funded research and development contracts, royalty income and grant revenues.
Revenues by Geographic Area. The following table represents total net revenues by geographic area, based on the location of the customer:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2026202520262025
United States$20,532 $19,662 $59,439 $60,070 
Africa6,399 4,875 19,959 19,023 
Europe2,223 1,300 5,415 5,064 
Other regions1,753 1,248 4,658 4,101 
$30,907 $27,085 $89,471 $88,258 
Customer Concentrations. The following table represents customer concentration risk:
For the Three Months Ended September 30,
Net Revenues20262025
Commercial customer(1)
10 %N/A
September 30,December 31,
Accounts Receivable20262025
Commercial customer (1)
20 %15 %
Commercial customer (1)
11 %N/A
(1) Each commercial customer is a different international distributor.
Vendor Concentrations. The Company currently purchases certain products and critical components of the Company's products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, the Company could be subject to increased costs and substantial delays in the delivery of the Company's products to its customers. Third-party suppliers also manufacture certain products. The Company's inability to have a timely supply of any of these components and products could have a material adverse effect on the Company's business, as well as the Company's financial condition and results of operations.
Deferred Revenue. The Company records deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of September 30, 2026 and December 31, 2025 was comprised of customer prepayments of $0.7 million and $1.2 million, respectively. Deferred revenue as of December 31, 2025 was also comprised of $0.4 million of unearned grant income. The Company had no unearned grant income in deferred revenue as of September 30, 2026.
The following table represents deferred revenue recognized:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
Deferred Revenue Recognized2026202520262025
Accrued at beginning of year$39 $529 $1,148 $1,991